At a Glance
- Company: Fujifilm Diosynth, Lonza, Samsung Biologics, WuXi Biologics
- Location: Global (Switzerland, South Korea, China, USA)
- Headline: Market to grow USD 16.32bn 2025–2030; $3bn+ capacity investments
- Focus area: ADCs, mAbs, PROTACs, RNAi, sterile fill‑finish
- Next steps: Facility expansions, strategic mergers
What happened?
Industry analyses identify Fujifilm Diosynth Biotechnologies, Lonza, Samsung Biologics and WuXi Biologics as the CDMOs best positioned for 2026 growth amid surging biologics demand. These leaders benefit from recent megadeals, including Samsung’s US$1.3bn biomanufacturing pact with a US pharma giant, and collective $3bn+ investments in capacity.
Why does it matter?
Biologics CDMO market hits USD 27.13bn in 2026, growing 7.14% CAGR to USD 38.29bn by 2031, driven by oncology/autoimmune therapies and outsourcing trends. Top players dominate via end‑to‑end services, single‑use tech and Asia expansion, capturing premium pricing for complex modalities.
Who’s behind it?
Fujifilm excels in continuous bioprocessing; Lonza in cell/gene and bioconjugation; Samsung/WuXi leverage Asia scale for mAbs/ADCs. Recent moves: WuXi’s Chengdu microbial DP plant; Samsung’s Songdo campus (360kL by 2030).
How was it achieved?
Scale, vertical integration and tech differentiation fuel leadership: Lonza’s Ibex for ADCs, Fujifilm’s MaruX lines. Asia hubs cut costs; mergers like BioCina/NovaCina build integrated challengers.
What’s next?
Expect more capacity online (Lonza Stein 2026, Samsung 2027); focus on CGT, viral vectors, sterile fill. Market bifurcation: scale leaders vs. niche specialists.
What are people saying?
Analysts: “Size matters… these CDMOs poised for biggest impact.” Forecasts highlight “strategic collaborations… in advanced therapies.”